publication_number,title,abstract,filing_date,grant_date,assignee,inventor,cpc_code
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"LUNDBERG, Ante Sven",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61P7/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N15/11
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N9/22
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/255
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/4535
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N15/102
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"EUSTACE, Brenda",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"MORAWA, Ewelina",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K2300/00
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K38/193
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"HO, TONY",C12N15/113
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/28
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"SANDLER, Laura",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"CHAKRABORTY, TIRTHA",A61K31/395
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/321
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"KAUFFMAN, ROBERT",C12N2310/315
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N5/0647
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",A61K35/18
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N2310/20
US-2025041349-A1,CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof,"Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.",20241028,0,Vertex Pharmaceuticals Incorporated,"ROSSERT, Jerome",C12N9/22
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K40/11
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K39/4613
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K39/4631
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K40/31
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K40/11
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K39/4613
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K39/4631
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K40/11
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K39/4611
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K39/4631
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K40/11
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K40/11
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K39/4631
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K39/4613
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",A61K40/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K40/31
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K40/31
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","VALAMEHR, BAHRAM",A61K39/4611
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K40/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/70535
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K39/4611
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/7051
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61K40/31
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C07K14/71
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/2302
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0696
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2502/30
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0646
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",C12N2501/15
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","LEE, Tom Tong",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C07K14/70503
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","PERALTA, EIGEN",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",A61K39/4611
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",A61K39/4631
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61K35/17
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N5/0636
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2510/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CARRON, Emily",C07K14/7155
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",A61P35/00
US-2025032547-A1,Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors,"Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.",20241016,0,"Fate Therapeutics, Inc.","CHU, Hui-yi",C12N2506/45
